PloS one

How Sleep Patterns Relate to Thinking Skills in Young People with Mood Disorders

Updated

Abstract

monitoring was completed in 152 young people with .

  • Cognitive performance in patients was poor on tasks related to mental flexibility and visual memory.
  • Three distinct groups of patients were identified based on sleep characteristics: 'long sleep', 'disrupted sleep', and 'delayed and disrupted sleep'.
  • Circadian profiles also revealed three clusters: 'strong circadian', 'weak circadian', and 'delayed circadian'.
  • Medication use varied between the identified sleep clusters.
  • The 'long sleep' cluster had significantly worse visual memory performance compared to the 'disrupted sleep' cluster.
  • Preliminary evidence suggests a relationship between sleep patterns and visual memory, potentially influenced by antipsychotic medication.

Simplified

Key numbers

RCFT 3 minute recall
Cognitive Performance Decrease
Long sleep cluster performed worse than disrupted sleep cluster.
31 of 152
Cluster Size
Long sleep cluster included 31 participants.
85 of 152
Cluster Size
Disrupted sleep cluster included 85 participants.

Full Text

What this is

  • This research investigates the relationship between sleep-wake cycles and cognitive functioning in young people with .
  • The study includes 152 young individuals diagnosed with and 69 healthy controls.
  • It identifies distinct sleep and circadian profiles and examines their associations with cognitive performance.

Essence

  • Distinct sleep and circadian profiles exist in young people with , with specific patterns linked to cognitive performance. The 'long sleep' cluster showed poorer visual memory compared to the 'disrupted sleep' cluster, suggesting a complex relationship between sleep and cognition.

Key takeaways

  • Three distinct sleep profiles were identified: 'long sleep', 'disrupted sleep', and 'delayed and disrupted sleep'. Each profile exhibited unique characteristics, such as sleep duration and timing.
  • The 'long sleep' cluster performed significantly worse on visual memory tasks compared to the 'disrupted sleep' cluster, indicating that longer sleep duration may not equate to better cognitive performance.
  • Medication use varied across clusters, with the 'long sleep' cluster having a higher proportion of participants on antipsychotics, which may influence cognitive outcomes.

Caveats

  • The study's cross-sectional design limits the ability to determine causality between sleep patterns and cognitive performance.
  • Potential selection bias from the help-seeking nature of participants may affect the generalizability of the findings.
  • Differences in medication among clusters complicate the interpretation of cognitive performance outcomes.

Definitions

  • Affective disorders: Mental health conditions characterized by significant changes in mood, including major depressive disorder, bipolar disorder, and anxiety disorders.
  • Actigraphy: A method of monitoring sleep and activity patterns using a wrist-worn device that records movement.

Simplified

Funding

Competing interests

Competing Interests: The authors have read the journal’s policy and have the following conflicts. DFH has received honoraria for educational seminars from Janssen-Cilag and Eli Lilly. EMS is the (unpaid) Clinical Director of Headspace Services at the BMRI, the (unpaid) Coordinator of the Youth Mental Health Research Program at the BMRI, and Deputy Director of St Vincent’s Private Hospital Young Adult Mental Health Unit. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. IBH is a Commissioner in Australia’s new National Mental Health Commission from 2012. He was a director of headspace: the national youth mental health foundation until January 2012. He was previously the chief executive officer (till 2003) and clinical adviser (till 2006) of beyondblue, an Australian National Depression Initiative. He is the executive director of the Brain and Mind Research Institute, which operates two early-intervention youth services under contract to headspace. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programs. He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of non-government organisations and the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, and Eli Lilly). He is a member of the Medical Advisory Panel for Medibank Private and also a Board Member of Psychosis Australia Trust. He leads an investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier-supported study of major depression and sleep disturbance in primary care settings. The competing interests do not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free